Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Carcinoma, Renal Cell 64Neoplasm Metastasis 25Kidney Neoplasms 21Neoplasms 16Breast Neoplasms 15Carcinoma, Non-Small-Cell Lung 13Urinary Bladder Neoplasms 12Prostatic Neoplasms 10Lung Neoplasms 8Brain Neoplasms 8Melanoma 7Colorectal Neoplasms 7Pancreatic Neoplasms 6Ovarian Neoplasms 6Neuroendocrine Tumors 6Liver Neoplasms 6Glioblastoma 6Gastrointestinal Stromal Tumors 6Carcinoma, Hepatocellular 6Thyroid Neoplasms 5Thymoma 5Small Cell Lung Carcinoma 5Recurrence 5Multiple Myeloma 5Esophageal Neoplasms 5Carcinoma 5Uveal Melanoma 4Stomach Neoplasms 4Sarcoma 4Adenocarcinoma 4

Interventions

tremelimumab 1pegfilgrastim 1durvalumab 1Sunitinib 1Paclitaxel 1Imatinib Mesylate 1Ifosfamide 1Darbepoetin alfa 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Dysgerminoma × Sunitinib × Clear all
NCT00453310 2015-10-27

Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
10 enrolled 6 charts
GenitourinaryGynecologic

Testicular Germ Cell Tumor, Dysgerminoma, Ovarian Neoplasms, Teratoma, Testicular Neoplasms, Carcinoma, Embryonal, Seminoma, Endodermal Sinus Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡